Metformin Beneficial for Osteoarthritis Knee Pain in Overweight, Obesity
THURSDAY, May 1, 2025 -- For patients with overweight or obesity and symptomatic knee osteoarthritis, metformin is associated with a greater improvement in knee pain than placebo, according to a study published online April 24 in the Journal of the American Medical Association to coincide with the 2025 Osteoarthritis Research Society World Congress, held from April 24 to 27 in Incheon, South Korea.
Feng Pan, Ph.D., from the School of Public Health and Preventive Medicine at Monash University in Melbourne, Australia, and colleagues examined the effects of metformin on knee pain at six months among patients with symptomatic knee osteoarthritis and overweight or obesity. Participants were recruited and followed remotely using telemedicine. Individuals with knee pain for six months or longer, a pain score of 40 mm on a 100-mm visual analog scale (VAS), and body mass index of 25 kg/m2 or higher were recruited and randomly assigned to receive oral metformin (2,000 mg/day) or identical placebo (54 and 53 participants, respectively) for six months.
The researchers found that the mean change in VAS pain was −31.3 and −18.9 mm in the metformin and placebo groups, respectively, at six months, corresponding to an effect size (standardized mean difference) of 0.43. Diarrhea and abdominal discomfort were the most common adverse events reported.
"These findings support a potential role of metformin in improving symptoms in individuals with knee OA and overweight or obesity," the authors write. "However, given the relatively small sample size, a confirmatory study is needed."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
THURSDAY, Sept. 18, 2025 -- In adults with obesity and those with type 2 diabetes and obesity, once-weekly semaglutide 7.2 mg is superior to placebo for body weight reduction...
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 -- Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with...
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
WEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.